Older people who are diagnosed with dementia have difficulty with tasks that require cognitive flexibility, such as remembering appointments to doctor visits and paying bills, according to new research published in the journal Neurology Open.
Researchers from the University of Birmingham studied four patients who met the criteria for a diagnosis of dementia. Individuals had a diagnosis of physical dementia and dementia based on the Alzheimer’s Disease Neuroimaging Index, which allows researchers to measure changes related to cognitive abilities and their related changes in brain activity since a patient first rediscovered independence in the 1980s. The three patients were randomly assigned to either a low-dose of intravenous immunoassay (IVI) to enhance insulin secretion to the brain or to receive room batwash for 12 hours per day. The IVI and room batwash treatment was given between November 2017 and October 2019.
The researchers found that the three older patients who were injected with IVI required manual dexterity tasks during tasks and showed a 30% increased probability of being able to think clearly, an 80% increased likelihood of being able to group numbers and an 82% increased likelihood of being able to do simple arithmetic. The IVI was administered between December 2018 and November 2019, but the researchers believe the beneficial effects on blood pressure, cognitive function and memory might also extend to longer term memory performance. This study is part of a larger and ongoing study with additional scientists at the University of Birmingham to examine the use of IVI and IVI room batwash for patients who have suffered from multiple sclerosis, multiple sclerosis with cirrhosis of the blood vessels, and Alzheimer’s Disease (AD) with special regard to memory and thinking skills.
Neil Fidler, Professor of Neurology at the University of Birmingham, said: “There are still a number of people who can benefit from the IVI brain-computer communication system. Our preliminary results indicate IVI room batwash may guarantee some of these previously diagnosed AD patients have improved cognitive function and are able to use their thinking skills. However, these improvements may not last and patients will need to continue to take daily medication for insulin to ensure a long-term improvement in cognitive ability. “